Insider · CIK 0001756211

Neumann Mark

Reports to the SEC for 2 companies · NEW HAVEN, CT

sec.gov

Transactions

Companies

Filings

CIK

0001756211

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-02-03	MANEVeradermics, Inc · Stock Option (Right to Buy)A Award	Chief Commercial Officer, Strategy Officer	AAward	+103K sh	—	—	102,885
2025-04-02	Intra-Cellular Therapies, Inc.D Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−52.8K sh	$132.00	−$6.97M	0
2025-04-02	Intra-Cellular Therapies, Inc.Stock Option (right to buy)D Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−17.9K sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Restricted Stock UnitsD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−13.1K sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Restricted Stock UnitsD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−17.5K sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Restricted Stock UnitsD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−22.7K sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Performance Stock UnitsA Award	EVP, Chief Commercial Officer	AAward	+13.1K sh	—	—	13,134
2025-04-02	Intra-Cellular Therapies, Inc.Performance Stock UnitsD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−13.1K sh	—	—	0
2025-04-02	Intra-Cellular Therapies, Inc.Performance Stock UnitsA Award	EVP, Chief Commercial Officer	AAward	+8,742 sh	—	—	8,742
2025-04-02	Intra-Cellular Therapies, Inc.Performance Stock UnitsD Disposition to Issuer	EVP, Chief Commercial Officer	DDisposition to Issuer	−8,742 sh	—	—	0
2025-03-10	Intra-Cellular Therapies, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+7,345 sh	—	—	55,927
2025-03-10	Intra-Cellular Therapies, Inc.F Tax Payment	EVP, Chief Commercial Officer	FTax Payment	−3,116 sh	$131.24	−$409K	52,811
2025-03-10	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−7,345 sh	—	—	0
2025-03-06	Intra-Cellular Therapies, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+13.1K sh	—	—	54,154
2025-03-06	Intra-Cellular Therapies, Inc.F Tax Payment	EVP, Chief Commercial Officer	FTax Payment	−5,572 sh	$131.19	−$731K	48,582
2025-03-06	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−13.1K sh	—	—	13,133
2025-03-01	Intra-Cellular Therapies, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+8,742 sh	—	—	44,730
2025-03-01	Intra-Cellular Therapies, Inc.F Tax Payment	EVP, Chief Commercial Officer	FTax Payment	−3,709 sh	$128.20	−$475K	41,021
2025-03-01	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−8,742 sh	—	—	17,485
2025-02-03	Intra-Cellular Therapies, Inc.Restricted Stock UnitsA Award	EVP, Chief Commercial Officer	AAward	+22.7K sh	—	—	22,727
2025-01-31	Intra-Cellular Therapies, Inc.A Award	EVP, Chief Commercial Officer	AAward	+11K sh	—	—	40,717
2025-01-31	Intra-Cellular Therapies, Inc.F Tax Payment	EVP, Chief Commercial Officer	FTax Payment	−4,729 sh	$127.00	−$601K	35,988
2024-08-16	Intra-Cellular Therapies, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+18.7K sh	$36.89	+$690K	48,414
2024-08-16	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−18.7K sh	$75.08	−$1.41M	29,700
2024-08-16	Intra-Cellular Therapies, Inc.Stock Option (right to buy)M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−18.7K sh	—	—	0
2024-03-11	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−4,303 sh	$65.11	−$280K	32,742
2024-03-11	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−1,729 sh	$65.92	−$114K	31,013
2024-03-11	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−1,313 sh	$66.86	−$87.8K	29,700
2024-03-10	Intra-Cellular Therapies, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+7,345 sh	—	—	37,045
2024-03-10	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−7,345 sh	—	—	7,345
2024-03-07	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−8,636 sh	$66.37	−$573K	34,196
2024-03-07	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−4,496 sh	$66.95	−$301K	29,700
2024-03-06	Intra-Cellular Therapies, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+13.1K sh	—	—	42,832
2024-03-06	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−13.1K sh	—	—	26,266
2024-03-01	Intra-Cellular Therapies, Inc.Restricted Stock UnitsA Award	EVP, Chief Commercial Officer	AAward	+26.2K sh	—	—	26,227
2024-02-26	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−200 sh	$68.03	−$13.6K	37,407
2024-02-26	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−4,059 sh	$69.56	−$282K	33,348
2024-02-26	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−2,341 sh	$70.70	−$166K	31,007
2024-02-26	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−1,307 sh	$71.18	−$93K	29,700
2024-02-23	Intra-Cellular Therapies, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+7,907 sh	—	—	37,607
2024-02-23	Intra-Cellular Therapies, Inc.Restricted Stock UnitsM Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−7,907 sh	—	—	0
2024-02-02	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−4,956 sh	$66.67	−$330K	36,604
2024-02-02	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−6,904 sh	$67.49	−$466K	29,700
2024-02-01	Intra-Cellular Therapies, Inc.A Award	EVP, Chief Commercial Officer	AAward	+11.9K sh	—	—	41,560
2023-11-06	Intra-Cellular Therapies, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+26.8K sh	$23.94	+$640K	72,093
2023-11-06	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−26.8K sh	$55.98	−$1.5M	45,339
2023-11-06	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−15.6K sh	$55.02	−$860K	29,700
2023-11-06	Intra-Cellular Therapies, Inc.Stock Option (right to buy)M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	−26.8K sh	—	—	0
2023-08-07	Intra-Cellular Therapies, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+55.3K sh	$18.59	+$1.03M	100,639
2023-08-07	Intra-Cellular Therapies, Inc.S Sale	EVP, Chief Commercial Officer	SSale	−55.3K sh	$58.79	−$3.25M	45,339

Recent filings

Accepted (ET)
Feb 54
Neumann Mark0001628280-26-005900
SEC(opens sec.gov)
Apr 24
Neumann Mark0000950170-25-049627
SEC(opens sec.gov)
Mar 104
Neumann Mark0000950170-25-036592
SEC(opens sec.gov)
Mar 44
Neumann Mark0000950170-25-032585
SEC(opens sec.gov)
Feb 44
Neumann Mark0000950170-25-013762
SEC(opens sec.gov)

Companies

Address

C/O VERADERMICS, INCORPORATED 470 JAMES ST.

NEW HAVEN, CT, 06513